OKYO Pharma Limited (OKYO) Research

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

Market snapshot

Symbol
OKYO
Price
$1.59
Day change
+1.27%
Market cap
$61.0M
P/E ratio
-12.90x
52-week range
1.42-3.349
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$7.00

Recent news

  • OKYO Pharma expands scientific advisory board with cornea expert - ICYMI

    OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances development of its lead ophthalmic candidate targeting neuropathic corneal pain.

  • OKYO Pharma expands scientific advisory board with cornea expert - ICYMI

    OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the appointment of Dr. Marta Sacchetti to its scientific advisory board as the company advances...

  • FTSE 100 Live: Stocks lose early gains as UK jobs market cools, IG and Currys surge

    FTSE 100 up 11 points at 10,335 UK jobs data weakens, unemployment back to 5% IG Group, Diploma, Currys, Dr Martens, SSP, Cranswick among reporters  ...

Peer companies

  • Anebulo Pharmaceuticals, Inc. (ANEB)
  • Clene Inc. (CLNN)
  • Coya Therapeutics, Inc. (COYA)
  • Immix Biopharma, Inc. (IMMX)
  • MacroGenics, Inc. (MGNX)
  • Pliant Therapeutics, Inc. (PLRX)
  • Sol-Gel Technologies Ltd. (SLGL)
  • Tiziana Life Sciences Ltd (TLSA)

Recent insider activity

  • Mantelli Flavio — trade (187500 shares) on 2030-02-10
  • Denoyer Bernard — A-Award (3500 shares) on 2026-06-08
  • BRANCACCIO JOHN P — A-Award (6500 shares) on 2026-06-08
  • Simon Willy Jules — A-Award (6500 shares) on 2026-06-08
  • Shah Keeren Rameshchandra — A-Award (40000 shares) on 2026-06-08

Open OKYO Pharma Limited (OKYO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.